Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563733 | 0.87 | LMNA (0.43) | KMT2ALMNAMEN1L3MBTL1PTPN1 | |
| SCHEMBL5986815 | 0.82 | ALDH1A1 (0.45) | KMT2ALMNAMEN1L3MBTL1PTPN1 | |
| SCHEMBL30286022 | 0.81 | POLB (0.49) | KMT2ALMNAMEN1L3MBTL1HPGD | |
| SCHEMBL5987827 | 0.81 | RAB9A (0.42) | KMT2ALMNAMEN1L3MBTL1PTPN1 | |
| SCHEMBL7370748 | 0.80 | LMNA (0.49) | KMT2ALMNAMEN1L3MBTL1PTPN1 | |
| SCHEMBL4267066 | 0.78 | SNCA (0.44) | CYP1A2CYP3A4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28114907 | 0.77 | CYP1A2 (0.56) | KMT2ALMNAMEN1HPGDCYP1A2 | |
| SCHEMBL25735701 | 0.76 | NQO2 (0.46) | KMT2AMEN1PTPN1CYP1A2RAB9A | |
| SCHEMBL6822002 | 0.75 | ALDH1A1 (0.52) | KMT2AMEN1HPGDCYP1A2CYP3A4 | |
| SCHEMBL28535807 | 0.75 | NPC1 (0.46) | KMT2ALMNAMEN1L3MBTL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1029851-B1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | KMT2A 2109/4885LMNA 4445/4885MEN1 4747/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | KMT2A 2049/4885LMNA 4420/4885MEN1 4758/4885 |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | TNF, CCR10, RELA | KMT2A 1815/4885LMNA 4306/4885MEN1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.